

# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias.


We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

## STOCK INFORMATION

### IRTC (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$64.14</b>
<b>Change (%)</b>	<b>▲ 2.40 (3.89%)</b>
<b>Volume</b>	240,148
<b>52 Week Low</b>	\$32.10
<b>Market Cap</b>	\$1,418,875,773
<b>Rolling EPS</b>	-1.30
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	22,981,467

Data as of 02/21/18 1:03 p.m. ET



## RECENT NEWS

Date	Title
02/14/18	<a href="#">iRhythm Technologies Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Full Year 2018 Financial Outlook</a>
02/07/18	<a href="#">iRhythm Technologies to Present at the RBC Global Healthcare Conference</a>
01/31/18	<a href="#">iRhythm Technologies to Report Fourth Quarter and 2017 Financial Results on February 14, 2018</a>

## UPCOMING EVENTS

Date	Title
02/21/18 3:30 p.m. ET	<a href="#">iRhythm Technologies Inc at RBC Capital Markets 2018 Healthcare Conference</a> <b>Location</b> New York Palace Hotel
05/23/18	<a href="#">iRhythm Technologies Inc Annual Shareholder Meeting</a> <b>Location</b> 650 Townsend Street, Suite 500 San Francisco, CA 94103

# SEC FILINGS

Filing Date	Form
02/14/18	8-K
02/14/18	SC 13G/A
02/14/18	SC 13G/A
02/13/18	SC 13G

Data provided by Nasdaq. Minimum 15 minutes delayed.